These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 2522344

  • 41. Antigen-induced cyclophosphamide-resistant suppressor T cells inhibit the in vitro generation of cytotoxic cells from one-way mixed leukocyte reactions.
    Bonavida B.
    J Immunol; 1977 Oct; 119(4):1530-3. PubMed ID: 142792
    [Abstract] [Full Text] [Related]

  • 42. A cyclophosphamide-sensitive suppressor T cell circuit induced by thermal injury.
    Kupper TS, Green DR, Chaudry IH, Fox A, Baue AE.
    Surgery; 1984 Jun; 95(6):699-706. PubMed ID: 6233740
    [Abstract] [Full Text] [Related]

  • 43. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
    Sobotková E, Nouza K.
    Neoplasma; 1993 Jun; 40(2):75-80. PubMed ID: 8350958
    [Abstract] [Full Text] [Related]

  • 44. Effect of cyclophosphamide on tumor cell sensitivity to the action of immunological effectors.
    Culo F, Marić M, Morović-Vergles J.
    In Vivo; 1995 Jun; 9(5):439-46. PubMed ID: 8900921
    [Abstract] [Full Text] [Related]

  • 45. Regulation of Ia+ reticulum cell sarcoma (RCS) growth in syngeneic SJL/J mice. I. Inhibition of tumor growth by passive administration of L3T4 monoclonal antibody before or after tumor inoculation.
    Ohnishi K, Bonavida B.
    J Immunol; 1987 Jun 15; 138(12):4524-9. PubMed ID: 2953807
    [Abstract] [Full Text] [Related]

  • 46. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB, Dray S.
    Cancer Res; 1983 Jul 15; 43(7):3112-9. PubMed ID: 6850619
    [Abstract] [Full Text] [Related]

  • 47. Regulation of the expression of adoptive tumor rejection immunity by recipient cyclophosphamide-sensitive cells.
    Boyer CM, Kreider JW, Bartlett GL.
    Cancer Res; 1982 Jun 15; 42(6):2211-5. PubMed ID: 7042079
    [Abstract] [Full Text] [Related]

  • 48. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
    Skundric DS, Huston K, Shaw M, Tse HY, Raine CS.
    Lab Invest; 1994 Nov 15; 71(5):671-9. PubMed ID: 7526038
    [Abstract] [Full Text] [Related]

  • 49. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
    Greenberg PD, Cheever MA.
    J Immunol; 1984 Dec 15; 133(6):3401-7. PubMed ID: 6149246
    [Abstract] [Full Text] [Related]

  • 50. The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.
    Culo F, Klapan I, Kolak T.
    Cancer Immunol Immunother; 1993 Dec 15; 36(2):115-22. PubMed ID: 8093855
    [Abstract] [Full Text] [Related]

  • 51. Studies on induction and control of cell-mediated autoimmunity. II. Prevention of induction and activity of autoreactive T cells by suppressor cells and by a suppressive serum factor.
    L'age-Stehr J, Diamantstein T.
    Eur J Immunol; 1978 Sep 15; 8(9):624-8. PubMed ID: 309399
    [Abstract] [Full Text] [Related]

  • 52. Phenotypic and functional modifications of thymocytes during tumor growth.
    Lombardi D, Naso G, Ottavio L, Lenti L, Mardente S, Pontieri GM.
    Thymus; 1992 Feb 15; 19(1):13-33. PubMed ID: 1566282
    [Abstract] [Full Text] [Related]

  • 53. Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin.
    Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H.
    Cancer Res; 1988 Dec 01; 48(23):6658-63. PubMed ID: 2460226
    [Abstract] [Full Text] [Related]

  • 54. Regulation of the immune response to tumor antigen.
    Greene MI, Perry LL, Benacerraf B.
    Am J Pathol; 1979 Apr 01; 95(1):159-69. PubMed ID: 373460
    [Abstract] [Full Text] [Related]

  • 55. [Effect of preliminary administration of allogenic cells on transplantation immunity in mice receiving cyclophosphamide].
    Cherniakhovskaia IIu, Fontalin LN, Rubakova EI.
    Biull Eksp Biol Med; 1978 Feb 01; 85(2):192-4. PubMed ID: 564721
    [Abstract] [Full Text] [Related]

  • 56. Inhibition of T suppressor cell function by local administration of an active cyclophosphamide derivative at the sensitization site.
    Limpens J, Scheper RJ.
    Clin Exp Immunol; 1991 Jun 01; 84(3):383-8. PubMed ID: 1828396
    [Abstract] [Full Text] [Related]

  • 57. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs.
    Bonmassar E, Testorelli C, Franco P, Goldin A, Cudkowicz G.
    Cancer Res; 1975 Aug 01; 35(8):1957-62. PubMed ID: 1149019
    [Abstract] [Full Text] [Related]

  • 58. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.
    North RJ, Awwad M.
    Immunology; 1990 Sep 01; 71(1):90-5. PubMed ID: 2145216
    [Abstract] [Full Text] [Related]

  • 59. Immune mechanisms in leukemia: suppression of cellular immunity by drugs and x-irradiation.
    Martinez D, Lukasewycz OA, Murphy WH.
    J Immunol; 1975 Sep 01; 115(3):724-9. PubMed ID: 1151076
    [Abstract] [Full Text] [Related]

  • 60. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
    Peppoloni S, Mathieson BJ, Herberman RB, Overton RW, Gorelik E.
    Cancer Immunol Immunother; 1987 Sep 01; 24(1):49-56. PubMed ID: 2949833
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.